3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
263
Leukemia
190
Leukemia, Lymphocytic, Chronic, B-Cell
166
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Myelodysplastic Syndromes
83
Lymphoma
79
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
71
Hematologic Neoplasms
62
Lymphoma, Non-Hodgkin
61
Lymphoma, Follicular
54
Leukemia, Myeloid, Chronic-Phase
53
Burkitt Lymphoma
51
Lymphoma, Large B-Cell, Diffuse
47
Lymphoma, B-Cell, Marginal Zone
45
Lymphoma, Mantle-Cell
44
Multiple Myeloma
42
Leukemia, Myelomonocytic, Chronic
41
Hodgkin Disease
41
Myeloproliferative Disorders
38
Neoplasms
37
Lymphoma, Large-Cell, Immunoblastic
37
Recurrence
31
Leukemia, Myeloid, Accelerated Phase
28
Congenital Abnormalities
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
26
Leukemia, Biphenotypic, Acute
26
Lymphoma, T-Cell, Cutaneous
25
Blast Crisis
24
Waldenstrom Macroglobulinemia
23
Leukemia, Myelomonocytic, Acute
23
Interventions
Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Herpes Zoster
×
Other hematologic neoplasm
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts